AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22724108
Drug: Nonthermal atmospheric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonthermal atmospheric pressure plasma (APP) treatment at the highest input voltage
Trial: 15777444
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (no cervical priming agent)
Trial: 12452759
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of salmeterol to low-dose fluticasone propionate
Trial: 12452759
Drug: Increasing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing the dose of fluticasone propionate
Trial: 8803398
Drug: 10 percent
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 percent carbamide peroxide gel
Trial: 8926595
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bisoprolol once daily for three weeks
Trial: 2046107
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (antihypertensive drug treatment with chlorthalidone and atenolol)
Trial: 6786204
Drug: Estrogen at
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen at half the treatment dose
Trial: 30885242
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA) with fentanyl through 48 h postsurgery
Trial: 27913279
Drug: Higher abrasivity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher abrasivity daily-use whitening dentifrice
Trial: 27129124
Drug: Enalapril oral
RxNorm normalized name: enalapril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril oral solution (1 mg/mL)
Trial: 27129124
Drug: Enalapril oral
RxNorm normalized name: enalapril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril oral solution with a high-fat meal
Trial: 27129124
Drug: Reference listed
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference listed drug (RLD) tablet
Trial: 19718777
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) administration
Trial: 17043680
Drug: Oral Delta(9)-tetrahydrocannabinol
RxNorm normalized name: delta 9-tetrahydrocannabinol acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Delta(9)-tetrahydrocannabinol (THC)
Trial: 17043680
Drug: Rectal THC-hemisuccinate
RxNorm normalized name: Hydrocortisone Hemisuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal THC-hemisuccinate (THC-HS)
Trial: 12506472
Drug: cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin (CDDP) 5 mg/body/day (i.v.) plus 5‐FU 300 mg/body/day (cvi) day 1‐5 for 6 weeks, followed by UFT 200 mg (as tegafur) x 2/day for as long as possible
Trial: 12506472
Drug: UFT only
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT only administered after surgery as long as possible
Trial: 9719743
Drug: Methylprednisolone 30
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 30 mg/kg intravenously 90 minutes prior to induction of anaesthesia (group 1)
Trial: 8573222
Drug: Pentalong 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentalong 50 mg tablets (2 tablets per dose)
Trial: 8573222
Drug: Aqueous suspension
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous suspension prepared from 25% PETN/lactose trituration
Trial: 7759705
Drug: Aminophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (6 mg/kg body weight over 15 min)
Trial: 2809002
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml of saline solution over 15 min)
Trial: 7636050
Drug: SCH 434
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 434 QD (10 mg loratadine + 240 mg pseudoephedrine sulfate)
Trial: 31037454
Drug: Slower rate
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slower rate of infusion of etomidate
Trial: 31037454
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction dose of etomidate
Trial: 2801064
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low dose heparin (5.000 IU) and dihydroergotamine (0.5 mg) given subcutaneously every twelve hours (n = 27)
Trial: 27632530
Drug: Computer-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based training program (special nonsense-syllables with background noise), 3 weeks, twice a week for 1 hour
Trial: 22682547
Drug: Alpha adrenergic
RxNorm normalized name: Alpha adrenergic receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha adrenergic blockers
Trial: 19724889
Drug: Glucosamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine administration (1.5 g and 3 g/day for 3 months)
Trial: 17179022
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg oral dose)
Trial: 11765110
Drug: Obstacles to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstacles to implementing pharmaceutical care programs
Trial: 31603191
Drug: Personalized antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antiplatelet therapy (according to maximum aggregation rate); if MAR > 55%, 90 mg ticagrelor twice daily plus 100 mg/day aspirin; if MAR ≤ 55%, 75 mg/day clopidogrel plus 100 mg/day aspirin
Trial: 31603191
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet treatment (75 mg/day clopidogrel plus 100 mg/day aspirin for at least 6 months)
Trial: 31603191
Drug: Personalized antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antiplatelet therapy
Trial: 31242860
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B deoxycholate 0.7-1.0 mg/kg/day for induction therapy
Trial: 31242860
Drug: Strategies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies to minimize/prevent phlebitis: 1 liter of IV normal saline after each dose, rotating IV catheters every three days, infusing IV amphotericin over 4 hours, encouraging early ambulation
Trial: 31242860
Drug: Warm compresses,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm compresses, topical diclofenac gel, and oral anti-inflammatory medicines for severe cases
Trial: 25955443
Drug: Mitii (web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitii (web-based therapy programme) for 20 weeks
Trial: 17940371
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation therapy
Trial: 15294364
Drug: Dinoprostone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone (0.5 mg intracervically every 6 h)
Trial: 11514956
Drug: Highly Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly Active Antiretroviral Therapy (HAART)
Trial: 9569468
Drug: Five-component pertussis
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-component pertussis combination vaccine (CPDT‐IPV//PRP‐T)
Trial: 9569468
Drug: Separate injection
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate injection of CPDT‐IPV and PRP‐T
Trial: 9569468
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell pertussis combination vaccine (DPT‐IPV//PRP‐T)
Trial: 9569468
Drug: Component vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Component vaccines (CPDT‐IPV)
Trial: 9569468
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell vaccine (DPT‐IPV)
Trial: 3410154
Drug: Salbutamol administered
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol administered from the Diskhaler (breath operated system)
Trial: 3410154
Drug: Salbutamol administered
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol administered from the metered dose inhaler
Trial: 27038550
Drug: Differential Depression
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differential Depression Treatment Response Index (DTRI)
Trial: 27038550
Drug: Biological markers
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological markers (DNA, RNA, plasma)
Trial: 27038550
Drug: Biological moderators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological moderators and mediators
Trial: 24714008
Drug: Crystalloid/colloid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid/colloid combination (750 ml crystalloid and 250 ml colloid)
Trial: 24714008
Drug: Colloid intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid intravenous fluid preload (500 ml)
Trial: 21404369
Drug: Methylphenidate combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate combined with multimodal behaviour therapy
Trial: 19400874
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) 100 mg/day
Trial: 19400874
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 400 mg/day
Trial: 17334460
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 2 mg/kg (Group K)
Trial: 17334460
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol 3 mg/kg and intravenous fentanyl 1 microg/kg with propofol infusion of 1 mg/kg/hr (Group PF)
Trial: 15166683
Drug: Methylphenidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.3 mg/kg/dose, twice a day)
Trial: 11777112
Drug: No-treatment comparison
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment comparison group
Trial: 9775459
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) phenobarbital 10 micrograms/kg (n = 42 newborns)
Trial: 27016000
Drug: BG00010 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG00010 (50, 150, 400, 800 μg kg(‐1) in Part I; 400, 600, 1200 μg kg(‐1) in Part II)
Trial: 18801405
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day plus ritanserin 12 mg/day (6 mg bid)
Trial: 15959636
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear treatment for at least 6 months achieving a minimum distalization of 4 mm
Trial: 28455746
Drug: Cervical headgear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical headgear treatment
Trial: 15314975
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients who had not undergone inductive chemotherapy)
Trial: 10894097
Drug: Talc slurry
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Talc slurry (5 grams mixed in 150 mL of normal saline)
Trial: 10894097
Drug: Bleomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin (1 unit per kilogram bodyweight mixed in 150 mL of normal saline)
Trial: 8895044
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg capsules once daily for 3 days)
Trial: 8895044
Drug: Co-amoxiclav (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (625 mg tablet three times daily for 5-10 days)
Trial: 8457082
Drug: Calcium-heparin (12,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-heparin (12,500 IU/day, subcutaneous)
Trial: 8457082
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg/day, oral)
Trial: 24470701
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy for insomnia (CBT-I), 4-week group-administered program
Trial: 19902183
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day of rimonabant for 2 weeks
Trial: 18049294
Drug: Methylphenidate 5
RxNorm normalized name: dexmethylphenidate 5.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 5 mg twice daily
Trial: 18049294
Drug: Methylphenidate 10
RxNorm normalized name: dexmethylphenidate 10.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 10 mg twice daily
Trial: 18049294
Drug: Methylphenidate 15
RxNorm normalized name: METHYLPHENIDATE 15MG/9HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 15 mg twice daily
Trial: 10519608
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) discontinued before administration of gonadotropins (study group)
Trial: 10519608
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) continued throughout the follicular phase (control group)
Trial: 10519608
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) discontinued before administration of gonadotropins (study group) in patients with non-persistently high basal FSH
Trial: 10519608
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) continued throughout the follicular phase (control group) in patients with non-persistently high basal FSH
Trial: 8480681
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (900 mg/d for 4 mo)
Trial: 1105627
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 or 20 mg)
Trial: 1105627
Drug: Fentanyl (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.1 or 0.2 mg)
Trial: 27096396
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement treatment
Trial: 19495810
Drug: Self-management treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management treatment
Trial: 25105516
Drug: GS-9620 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9620 (0.3, 1, 2 and 4 mg)
Trial: 25105516
Drug: GS-9620 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9620 (1, 2 and 4 mg)
Trial: 21428241
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg (test formulation)
Trial: 21428241
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg (reference formulation)
Trial: 19231325
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (medical treatment)
Trial: 16987370
Drug: Propofol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5 mg/kg followed by 50 microg/kg/min)
Trial: 14692166
Drug: Tooth-whitening gel
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tooth-whitening gel (Colgate Simply White Night Clear Whitening Gel) used once daily at night in addition to a commercially available dentifrice.
Trial: 14692166
Drug: Tooth-whitening gel
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tooth-whitening gel (Colgate Simply White Night Clear Whitening Gel) used once daily at night.
Trial: 8113493
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training therapy
Trial: 30169192
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 3 μg/kg
Trial: 30169192
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 3 μg/kg (in boys)
Trial: 25506618
Drug: Motor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor therapy focusing on the nonparetic side along with the conventional program
Trial: 8709183
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and IVGG 400 mg/kg/day for 5 consecutive days
Trial: 8709183
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and single high dose IVGG (2 gm/kg) for 10-12 hours
Trial: 31014147
Drug: Dexmedetomidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine treatment group (n=25)
Trial: 29785101
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 µg once-daily maintenance therapy
Trial: 24700398
Drug: CC/Gn/GnRH‐ant 'mild'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC/Gn/GnRH‐ant 'mild' protocol
Trial: 24700398
Drug: GnRH‐agonist and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐agonist and high‐dose Gn 'long' protocol
Trial: 17459013
Drug: Self-reported willingness-to-pay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported willingness-to-pay (WTP) for a theoretical treatment with a cure rate of 85%
Trial: 15226331
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m² on days 1 through 5, four cycles, every 3 weeks)
Trial: 11343045
Drug: Montelukast 5
RxNorm normalized name: montelukast 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 5 mg added to budesonide 200 microg twice daily
Trial: 11343045
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to budesonide 200 microg twice daily
Trial: 9633737
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone 10 mg every 12 hours, increased weekly up to a maximum of 30 mg every 12 hours
Trial: 3348138
Drug: Isosorbide‐5‐mononitrate 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate 10 mg
Trial: 3348138
Drug: Isosorbide‐5‐mononitrate 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate 20 mg
Trial: 3348138
Drug: Isosorbide‐5‐mononitrate 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate 50 mg
Trial: 30269642
Drug: Solriamfetol 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 600 mg
Trial: 30269642
Drug: Solriamfetol 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 1200 mg
Trial: 24743717
Drug: Intramuscular olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular olanzapine 10 mg/d
Trial: 24743717
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol 7.5 mg/d
Trial: 22549239
Drug: Ciprocare®XR 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprocare®XR 1000 mg ciprofloxacin (test formulation)
Trial: 22549239
Drug: Cipro®XR sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipro®XR sustained release tablet (reference formulation)
Trial: 20927040
Drug: Ultrafiltration rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrafiltration rates over 13 ml/h/kg
Trial: 20927040
Drug: Ultrafiltration rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrafiltration rates between 10-13 ml/h/kg
Trial: 20927040
Drug: Ultrafiltration rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrafiltration rates up to 10 ml/h/kg
Trial: 10825337
Drug: Clonidine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.15 mg oral dose 90 min before surgery
Trial: 1725027
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of ramipril